Drug – bio-affecting and body treating compositions – Lymphokine – Interferon
Reexamination Certificate
2005-05-10
2005-05-10
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Lymphokine
Interferon
C514S028000, C514S152000, C514S192000, C514S252130, C514S253080
Reexamination Certificate
active
06890526
ABSTRACT:
The invention features methods and reagents for the diagnosis, monitoring, and treatment of multiple sclerosis. The invention is based in part on the discovery thatChlamydiais present in patients with multiple sclerosis, and that anti-chlamydial agents improve or sustain neurological function in these patients.
REFERENCES:
patent: 3996355 (1976-12-01), Lin et al.
patent: 5217493 (1993-06-01), Raad et al.
patent: 5650405 (1997-07-01), Remington et al.
patent: 5795563 (1998-08-01), Kallick
patent: 5869608 (1999-02-01), Caldwell et al.
patent: 6043225 (2000-03-01), Shor et al.
patent: 6043227 (2000-03-01), Cheng et al.
patent: 6057367 (2000-05-01), Stamler et al.
patent: 6710033 (2004-03-01), Stratton et al.
patent: 1 156 589 (1997-08-01), None
patent: 1 190 581 (1998-08-01), None
patent: 0439330 (1991-01-01), None
patent: 0699688 (1996-03-01), None
patent: 2134292 (1972-08-01), None
patent: WO 9000061 (1990-01-01), None
patent: WO 9806408 (1998-02-01), None
patent: WO 9806435 (1998-02-01), None
patent: WO 9810789 (1998-03-01), None
patent: WO 9817280 (1998-04-01), None
patent: WO 9824362 (1998-06-01), None
patent: WO 9847509 (1998-10-01), None
patent: WO 9850074 (1998-11-01), None
patent: WO 9851696 (1998-11-01), None
patent: WO 9858953 (1998-12-01), None
patent: WO 9917741 (1999-04-01), None
patent: WO 9921865 (1999-05-01), None
patent: WO 9921866 (1999-05-01), None
patent: WO 0001378 (2000-01-01), None
Appelt et al., “Is there an association of β-Amyloid withChlamydia pneumoniaein glial and monocyte cell lines infected with the bacterial isolates obtained from alzheimer disease brains?”Society for Neuroscience Abstracts25:42 (1999).
Balin et al., “Identification and localization ofChlamydia pneumoniaein the Alzheimer's brain,”Society for Neuroscience Abstract24:1957 (1998).
Balin et al., “Identification and localization ofChlamydia pneumoniaein the Alzheimer's Brain,”Medical Microbiology and Immunology187:23-42 (1998).
Bertrand et al., “L'ofloxacine (Ru 43280) étude clinique”Pathologie- Biologie35: 629-633 (1987), english abstract considered.
Brocke et al., “Induction of relapsing paralysis in experimental autoimmune encephalomyelitis by bacterial superantigen,”Nature365:642-644 (1993).
Drancourt et al., “Oral rifampin plus ofloxacin for treatment ofstaphylococcus-infected orthopedic implants”Antimicrobial Agents and Chemotherapy37:1214-1218 (1993).
Freidank et al., “In vitro susceptibilities ofChlamydia pneumoniaeisolates from german patients and synergistic activity of antibiotic combinations,”Antimicrobial Agents and Chemotherapy43:1808-1810 (1999).
Gieffers et al., “Failure to detectChlamydia pneumoniaein brain sections of Alzheimer's disease patients,”Journal of Clinical Microbiology38:881-882 (2000).
Jahnke et al., “Sequence homology between certain viral proteins and proteins related to encephalomyelitis and neuritis,”Science229:282-284 (1985).
Korman et al., “Neurological complications of chlamydial infections: case report and review,”Clinical Infectious Disease25:847-851 (1997).
Kurtzke, “Epidemiologic evidence for multiple sclerosis as an infection,”Clinical Microbiology Reviews6:382-427 (1993).
Layh-Schmitt et al., “Evidence for Infection withChlamydia pneumoniaein a subgroup of patients with multiple sclerosis,”Annals of Neurology47:652-655 (2000).
LeGac et al., “Sur une etiologie rickettsienne et neo-rickettsienne possible de la sclerose en plaques,”Comptes rendus250: 1937-1938 (1960).
LeGac, “Le traitement de la sclerose en plaques d'origine rickettsienne ou neo-rickettsienne,”Comptes rendus250: 2474-2476 (1960).
LeGac, “Le probleme histo-physio-patho-logique de la sclerose en plaques,”Comptes rendus250: 2299-2303 (1960).
LeGac et al, “Le virus de la psittacose dans l'etiologie de la sclerose en plaques,”Comptes rendus263:1793-1797 (1966).
LeGac, “Rickettsioses, pararickettsioses et systeme nerveux,”Annali dell'Istituto superiore di sanita10:275-296 (1974).
LeGac et al., “Resultats de L'antibiotherapie a large spectre sur 30 cas chroniques de sclerose en plaques rickettsienne et neo-rickettsienne,”Bulletin de la Societie de Pathologie Exotique2:263-276 (1964).
McHatters et al., “Bird viruses in multiple sclerosis: combination of viruses or Marek's alone?”Neuroscience Letters.188:75-76 (1995).
Nochlin et al., “Failure to detectChlamydia pneumoniaein brain tissue of Alzheimers's disease,”Neurology53:1888 (1999).
Oldstone, “Virus-induced autoimmunity: molecular mimicry as a route to autoimmune disease,”Journal of Autoimmunity2(S):187-194 (1989).
Perlmutter et al., “Possible relationship of chlamydia to multiple sclerosis”Medical Hypotheses12:95-98 (1983).
Renvoize et al., “A sero-epidemiological study of conventional infectious agents in Alzheimer's disease,”Age and Ageing16:311-314 (1987).
Rosenkranz, “Rifampicin and multiple sclerosis,”The Lancet2:1370 (1972).
Sever et al., “Virus antibodies and multiple sclerosis,”Archives Neurology24:489-494 (1971).
Sriram et al., “Multiple sclerosis associated withChlamydia pneumoniaeinfection of the CNS,”Neurology50:571-572 (1998).
Sriram et al., “C.pneumoniaeinfection of the CNS in patients with relapsing remitting MS,”Neurology52:A558-A559 (1999).
Sriram et al., “Chlamydia pneumoniaeinfection of the central nervous system in multiple sclerosis,”Annals of Neurology46:6-14 (1999).
Sriram et al., “Indictment of the microglia as the villian in multiple sclerosis,”Neurology48:464-470 (1997).
Yao et al., “Association betweenC. pneumoniaeand MS,”Journal of Neuroimmunology90:70 (1998).
Yao et al., “CNS infection withC. pneumoniaein MS,”Neurology50:A423-A424 (1998).
Yao et al., “Reactivity of oligoclonal bands seen in CSF toC. pneumoniaeantigens in patients with multiple sclerosis,”Neurology52:A559 (1999).
Mitchell William M.
Sriram Subramaniam
Stratton Charles W.
Clark & Elbing LLP
Krishnan Ganapathy
Vanderbilt University
Wilson James O.
LandOfFree
Methods and reagents for the treatment of multiple sclerosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and reagents for the treatment of multiple sclerosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and reagents for the treatment of multiple sclerosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3454354